Kornimate/medical-research-clean huggingface dataset:
a randomized controlled study on the treatment of sacral canal cysts with sacral canal reinforcement

Conditions: Tarlov Cysts

Summary: the subject will treat 68 patients with symptomatic sacral canal cysts as the research object, and adopt a randomized controlled research method, respectively, using two methods of reinforcement and reconstruction of the nerve root sleeve, sacroplasty and nerve root sleeve plasty, and observed the operation of the patient complications, preoperative and postoperative short-term and long-term vas pain scores, joa neural function scores, and changes in cyst size on imaging examinations, to evaluate the safety of nerve root sleeve reconstruction and sacroplasty in reducing the safety of postoperative cyst recurrence sex and effectiveness, so as to further improve the surgical treatment of sacral canal cysts, improve the curative effect, and formulate the operation specifications for the treatment of sacral canal cyst

in this subject, a cohort observation method was used to observe 52 patients with two types of surgical removal of hematoma in the basal ganglia under the guidance of frontal ultrasound through keyhole neuroendoscopy and microsurgery for hematoma removal under the guidance of frontal ultrasound. they were divided into endoscopic surgery group and microsurgery. in the endoscopic surgery group, 26 cases were treated with keyhole neuroendoscopy under the guidance of frontal ultrasound for hematoma removal in the basal ganglia area, and 26 cases in the microsurgery group were treated by craniotomy microsurgery hematoma removal surgery. observe the removal rate of surgical hematoma in the two groups and the safety of the operation and the gcs score, gos score and mri examination of nerve fiber damage and postoperative complications at 1 week, 1 month, and 3 months after the operation. observe and analyze the improvement of the hematoma clearance rate in the endoscopic surgery group. and whether it has an advantage in terms of efficacy

Eligibility criteria:
inclusion criteria: 1. symptomatic nerve root cysts diagnosed by mri 2. intact cyst capsule, no defect of sacral canal lamina 3. no other diseases of nervous system, pelvic floor and important organs 4. agree inclusion exclusion criteria: a ) non-radiculent cysts or asymptomatic cysts b) cysts cause severe bone erosion to lamina resorption c) combined with other diseases of nervous system, pelvic floor and important organs d) disagree to join e) cannot complete follow-up -

Keywords: tarlov cysts surgery
effect of intraarticular ozone, prolotherapy or dexmedetomidine in pain limitation in knee osteoarthritis

Conditions: Intraarticular; Ozone; Prolotherapy; Dexmedetomidine; Pain; Knee Osteoarthritis

Summary: this study aimed to compare intraarticular ozone injection, prolotherapy, or dexmedetomidine effectiveness in knee osteoarthritis patients.

osteoarthritis (oa) is a heterogeneous group of disorders of different etiologies with similar biological, morphological, and clinical manifestations and outcomes. the intraarticular injection has been recommended to alleviate the pain in the knee joint. ozone therapy has long been used in the management of oa. furthermore, it has been shown to not cause a significant inflammation process or cartilage degradation. prolotherapy is a procedure where a natural irritant is injected into the soft tissue of an injured joint. dexmedetomidine is a selective α2-adrenergic agonist with considerable sedative and analgesic actions.

Eligibility criteria:
inclusion criteria: * age from 30 to 65 years. * both genders. * patients diagnosed with stage 1-3 osteoarthritis according to the kellgren-lawrence classification system (k-l). exclusion criteria: * patient refusal. * history of knee trauma within the past month. * rheumatic disease. * pregnancy. * any surgical intervention of the knee. * severe cardiovascular disease. * morbid obese patients (body mass index (bmi) of \>35 kg/m2). * local infection at the site of injection. * bleeding diathesis.
incidence and relationship of positive preoperative methicillin resistant staphylococcus aureus (mrsa) screens and post-operative infections

Conditions: Methicillin-resistant Staphylococcus Aureus Infection

Summary: the purpose of this study is to evaluate the prevalence of pre-surgical patients who are mrsa carriers. from an evidence-based practice perspective, findings from this study can be considered in the evaluation of the hospital sop mandating pre-surgical mrsa screening requirements for patients with scheduled surgeries. the central hypothesis to be addressed in this study is whether the mrsa colonization and subsequent post-operative infection are the equivalent in these populations.

design and methods: subjects in this study of 975 pre-operative, scheduled surgical patients are in one of the three following groups: * group 1 (n=325): allocation sample of surgical patients required to be mrsa screened per hospital sop (including patients having a positive mrsa history, orthopedic surgery, undergoing dialysis, or transfer from another hospital, nursing home, skilled nursing facility, or jail). * group 2 (n=650): randomized sample (1:1 ratio) of surgical patients not required to be mrsa screened per hospital sop, to one of the following two groups: * 2a (n=325): mrsa screening; or * 2b (n=325): no mrsa screening. all subjects were followed for 30 days post-operatively to determine the incidence of post-operative infection. treatment, diagnostic, and hospitalization data were collected for patients diagnosed with post-operative infection.

Eligibility criteria:
inclusion criteria: 1. pre-surgical out patient at ilh 2. surgical procedure scheduled at least 2 days before surgery 3. surgery being done at ilh operating room 4. provision of signed icf exclusion criteria: 1. patient 18 years of age or older who is deemed by the hospital incapable of providing informed consent 2. inability to communicate in the english language

Keywords: preoperative screening mrsa incidence postoperative infection preoperative mrsa screening incidence postoperative mrsa infection rate
unicentric form of castleman disease - surgery therapy benefit

Conditions: Castleman Disease; Unicentric Castleman Disease; Surgery

Summary: observation study on patients with unicentric form of castleman disease, evaluation of surgical treatment benefit. observation of surgical treatment strategy.


Eligibility criteria:
inclusion criteria: * patient with unicentric form of castleman disease * underwent surgery resection exclusion criteria: * multilocalised castleman disease

Keywords: unicentric form of castleman disease surgical resection
organoids based drug sensitivity in neoadjuvant chemotherapy of breast cancer

Conditions: Organoids; Breast Cancer; Neoadjuvant Chemotherapy

Summary: breast cancer is the most common malignancy in women worldwide. patients with breast cancer are often diagnosed at later stages and have a strong desire for breast conservation, necessitating neoadjuvant chemotherapy. tumors of different molecular subtypes and individual variations among patients lead to significant differences in treatment efficacy. precise assessment of patients' responses to treatment regimens is imperative in advancing prognosis of breast cancer. in this study, 58 patients diagnosed with breast cancer and scheduled for neoadjuvant therapy will be recruited. patient-derived organoids from their tumor biopsies will be utilized to evaluate the sensitivity of chemotherapy regimen. these drugs primarily include doxorubicin, carboplatin, cyclophosphamide, paclitaxel, as well as targeted therapies such as herceptin and pertuzumab.

58 early-stage breast cancer patients scheduled to undergo neoadjuvant therapy will be recruited. baseline information including medical history, ultrasound, breast-specific gamma imaging (bsgi), and magnetic resonance imaging (mri) records, will be collected both before and after two cycles of chemotherapy. tumor tissue from these patients will be obtained via biopsies guided by ultrasound. patient-derived organoids (pdos) will be established and cultured from the collected tumor tissue. subsequently, these pdos will be subjected to treatment with drugs from standard chemotherapeutic regimens for breast cancer. the growth of the organoids will be assessed post-treatment, and dose-response curves will be generated. for evaluating the clinical outcomes of the patients, the residual cancer burden (rcb) system will be used to evaluate tumor histological responses in patients. the consistency between treatment responses observed in the pdo models and the clinical outcomes of patients will be evaluated through correlation analysis.

Eligibility criteria:
inclusion criteria: 1. signed informed consent form and willingness to participate in the clinical study. 2. female patients aged between 18 and 70 years old. 3. confirmed early-stage breast cancer eligible for surgery (ajcc stages i to iiia), with a tumor diameter of ≥ 2cm detected by mri and without distant metastasis (m0). the largest lesion among multiple lesions has a diameter of ≥ 2cm. 4. ecog performance status score of 0-1. 5. no significant abnormalities in liver and kidney function (bil \<1.5-fold upper limit of normal (uln)；alt\<2.5×uln; ast\<2.5×uln；crea≤1×uln). exclusion criteria: 1. received prior treatments. 2. locally advanced breast cancer not amenable to surgery or inflammatory breast cancer (ajcc stage unresectable iii). 3. bilateral breast cancer. 4. multiple breast cancers distributed in different quadrants. 5. patients not suitable for neoadjuvant chemotherapy.
measurement and analysis of gas composition in digestive tract

Conditions: Inflammatory Bowel Diseases; Irritable Bowel Syndrome; Functional Dyspepsia; Colorectal Neoplasms; Helicobacter Pylori Infection

Summary: the purpose of this study is to detect the concentration of various gases，including hydrogen, methane, hydrogen sulfide, nitric oxide in different parts of the digestive tract by a safe and direct method, and to establish a human digestive tract gas profiles. analyze the differences in gas components in different segments of the digestive tract in patients with different diseases, and analyze the correlation between specific gases and digestive tract diseases and non-specific symptoms.


Eligibility criteria:
inclusion criteria: * patients aged 18 to 70 years. * patients undergoing endoscopic examination exclusion criteria: * patients with serious underlying diseases, such as liver insufficiency, renal insufficiency, immunosuppression, coronary heart disease (angina pectoris or coronary artery stenosis ≥ 75%). * patients have history of gastrointestinal surgery * patients who failed to complete the endoscopic examination due to various reasons * patients boston score of bowel preparation≤ 6 points * patients who have medication history of probiotics, antibiotics, ppis and prokinetic drugs in the last 4 weeks * patients who combined with thyroid disease and other diseases that affect gastrointestinal motility * patients who combined with other risk factors such as mental illness, alcoholism, and drug abuse * patients who unable or unwilling to provide informed consent
effectiveness and safety of mesenchymal stem cell (msc) implantation on degenerative discus disease patients

Conditions: Degenerative Disc Disease; Low Back Pain; Disc Degeneration

Summary: this study evaluates the effectivity and safety of msc implantation on degenerative disc disease patients by assessing visual analog scale, rom improvement and mri examination.

the team plan to conduct research to look at the effectiveness and safety of mesenchymal stem cell implantation therapy in intervertebral disc degeneration patients. the use of allogenic mesenchymal stem cells from the umbilical cord was chosen because patients with degeneration of the intervertebral disc are elderly (over 50 years old) so that autologous mesenchymal stem cell administration is not possible in terms of taking the source of cells (bone marrow) nor the quality of mesenchymal stem cells obtained. this study will assess the improvement of clinical symptoms (vas to assess pain scale, asia and frankel scale, as well as assessment of the widening of the lumbar region using the schober test), changes in the structure of the intervertebral discs (through mri examination and grading the degree of intervertebral disc degeneration), conduction function spinal cord nerve (somatosensory evoked potential / ssep), myelography / emg, and assessment of the quality of life status of patients using the oswestry disability index.

Eligibility criteria:
inclusion criteria: 1. patients enrolled in cipto mangunkusumo hospital with degenerative disc disease with no promising result after conventional treatment. 2. no history of metabolic, autoimun and genetic disease(s). 3. no active infection (hbsag, hiv, cmv, rubella). 4. agree to participate the study by signing informed consent form. exclusion criteria: 1. patients under 20 years old. 2. declined to participate in the study.

Keywords: ddd msc
transcranial direct current stimulation (tdcs) cost-utility-analysis in medical care on depressive episode with one drug therapy failure.

Conditions: Depression

Summary: the purpose of this study is to determine the transcranial direct current stimulation (tdcs) cost-utility in the depression therapy. this is a 3 years medico-economics study with 1 year follow-up period involving patients with 1 or 2 depression treatment(s) failed. eligible subject will be randomized in 2 groups, usual care with tdcs cure (arm a) or only usual care (arm b).

transcranial direct current stimulation is a non-invasive brain neuromodulation technique. tdcs can be a new therapy in depression. this study focuses on tdcs cost-utility-analysis. each patient is following during 12 months. patients are randomized in 2 arms. arm a usual care with tdcs cure or arm b usual care without tdcs. patient in arm a get a initial tdcs cure one week after randomization. if these patients are answering to the treatment, they can have a new cure in case of relapse. this new cure can start from the second month following initial treatment.

Eligibility criteria:
inclusion criteria: * depression according to diagnostic and statistical manual of mental disorders, fifth edition (dsm-v) with 1 or 2 failed antidepressant treatments for the current episode. * madrs score superior or equal to 15. * patient agreeing to participate in the study * patient able to answer questionnaires and able to go at research center for follow-up visit. * patient with social insurance exclusion criteria: * electroconvulsive therapy or repetitive transcranial magnetic stimulation for current depressive episode. * depressive episode with psychotic symptoms or mixed. * schizophrenia or addiction to another substance than nicotine * severe neurological disorder (like epilepsy, neurological affect, neurological disease) * severe and / or progressive somatic pathology (leave to the investigator judgment) preventing from participation in the study. * tdcs specific contraindications (intracerebral metallic implant, pacemaker) * pregnancy or breast feeding. * woman of childbearing age without contraception (hormonal or with medical device). * participation in another interventional clinical trial * legal protection * persons incarcerated or in obligation of treatment / medical treatment order.

Keywords: depression psychiatry health economics neurostimulation tdcs
a case series of vpia using remifentanil for labour and delivery

Conditions: Labor Pain

Summary: this study is a prospective case series aiming to evaluate a new vpia remifentanil algorithm which would benefit labouring mothers who are unable or unwilling to receive epidural analgesia.

this study proposes a novel vital signs-controlled, patient-assisted intravenous analgesia (vpia) regimen that will enhance the efficacy, safety and personalization of remifentanil therapy for labouring women. this system will study the parturient's pattern of analgesic use in 15 min epochs and titrate the demand doses and basal infusion rate to maintain a plasma level of remifentanil that is appropriate for the degree of pain felt. the system incorporates vital signs (pulse oximetry and heart rate values) into the algorithm which would temporarily stop the pumps and step down doses accordingly when predefined critical values are reached.

Eligibility criteria:
inclusion criteria: * patients who choose to use parenteral opioid for pain relief with informed consent * patients who refuse labour epidural analgesia * patients with contraindication to epidural analgesia (eg. thrombocytopaenia, previous thoraco-lumbar spinal instrumentation) exclusion criteria: * patients who are unable to understand instructions given regarding the use of patient controlled analgesia (pca) or unable to self administer pca boluses * patients with difficulty in communication due to language differences * patients with known hypersensitivity to remifentanil or any component of its formulation or to other fentanyl analogs * patients with severe respiratory disease * patients with history of drug dependence of recreational drug abuse * patients with unmanaged foetal bradycardia

Keywords: remifentanil labour analgesia
four mandibular implant-retained overdentures in individuals with type 2 diabetes

Conditions: Bone Resorption

Summary: studies clinically evaluate the long-term outcome of 4 implant attachment-retained mandibular ovds among patients with high glycemic levels are lacking.

chronic hyperglycemia is considered as a typical risk-factor that causes soft tissue inflammation and bone loss around natural teeth and implants. one possible explanation for this mechanism is that chronic hyperglycemia has the propensity to increase the levels of accumulated glycation end products (ages) in the serum and oral tissues that accelerates the production of proinflammatory cytokines that induce bone destruction around natural teeth and implants. however, it is relevant to indicate that dental implants in chronic hyperglycemia under ideal glycemic conditions can successfully osseointegrate and show predictable outcomes over long durations in both diabetic and non-diabetic patients. studies clinically evaluate the long-term outcome of 4 implant attachment-retained mandibular ovds among patients with high glycemic levels are lacking.

Eligibility criteria:
inclusion criteria: * patients with edentulous maxilla and mandible for at least 12 months. * patients have problems with mandibular denture retention and stability. * patients with a mandibular bone height measured on a panoramic x-ray between 15 and 25 mm at the mandibular symphysis region. exclusion criteria: * patients who did not receive implants at the department clinic. * patients with more or less than 4 implants in the mandible. * patients with well controlled diabetics. * patients with relative contraindications, such as a history of parafunctional habits, daily smokers of more than 10 cigarettes, or alcoholism. * patients who have previously received head and neck radiation therapy; furthermore, patients receiving intravenous bisphosphonates, chemotherapy, or psychological disorders could jeopardize their cooperation.
a study to determine the safety and efficacy of a new non-invasive heating garment to reduce urinary hesitancy

Conditions: Benign Prostatic Hyperplasia (BPH); Urinary Retention; Urinary Hesitancy Intermittent

Summary: to determine the safety and efficacy of the thermarx heating device for the application of controlled low level heat to improve symptoms of lut dysfunction (hesitancy, urgency).

this study will assess the safety and efficacy of thermarx heat treatment in subjects who have urinary hesitancy. the rationale for this approach is based on anecdotal evidence and case reports suggesting that urinary hesitancy can be effectively reduced by external skin heating (hot tub "jacuzzi" effect, perineal hot water spray). however, to date, there have been no formal studies of this non-invasive form of treatment, and the mechanism of action is still unclear. this is a two-day study in which each subject will receive an oral fluid load and then one (1) heating treatment with the device. ultrasound-based measurements of bladder volume will be performed both before and after voiding. on day 1, voiding will be performed in a standing position; on day 2, voiding will be done in a sitting position.

Eligibility criteria:
inclusion criteria: * male subjects 25-80 years of age at the screening visit. * subject must have mild-to-moderate urinary hesitancy symptoms (shown as an american urological association symptom index (aua-si) score of 7-19). * symptoms include (not limited to): * leaking or dribbling of urine * more frequent urination, especially at night * urgency to urinate * urine retention (inability to urinate) * hesitant, interrupter or weak stream of urine * inability or difficulty to urinate in public exclusion criteria: * history of prostate cancer or prostate surgery * currently (or within the past 30 days) on active treatment for prostate problems

Keywords: benign prostatic hyperplasia bph benign prostatic hypertrophy urinary retention shy bladder urinary hesitancy bashful bladder paruresis
vaginal laser therapy in breast cancer survivors

Conditions: Genitourinary Syndrome of Menopause; Vaginal Atrophy; Breast Cancer; Dyspareunia

Summary: this study evaluates the efficacy of vaginal co2 laser therapy in breast cancer survivors with symptoms of genitourinary syndrome of menopause. half of participants will receive active laser therapy, while the other half placebo therapy.


Eligibility criteria:
inclusion criteria: * breast cancer history * dyspareunia * dryness exclusion criteria: * active genital infection (i.e herpes, vaginitis) * prolapse stage \>=2 * underlying pathologies that could interfere with the protocol compliance